Fall 2018 Ohio TTP & aHUS Support Group Meeting

The Ohio State University TTP/aHUS face-to-face meeting was made available to non-local participants to join virtually. On Wednesday November 7th, Dr. Cataland presented a great layman explanation about the role of the ADAMTS13 enzyme in TTP. In addition, he thoughtfully answered questions from both the face-to-face and virtual audiences about TTP triggers, treatments, side effects and more. On an exciting note, he explained the role of a new drug called caplacizumab.

Dr. S. Cataland

The audience was invited to learn more about participating in research by contacting them or their local Consortium location.

Missed it the first time. Listen to the recording at http://go.osu.edu/ttp_ahus_support.